Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05976516
Other study ID # 20220224016
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date August 1, 2023
Est. completion date March 30, 2024

Study information

Verified date July 2023
Source Zhongda Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Low back pain (LBP) is the largest cause of morbidity in the world, and about 80% of Chinese people are affected in their lifetime. Although the prevalence of IDD gradually increases with age, IDD is very common among subjects under 30 years old. In addition to age, there are other factors, such as excessive or uneven mechanical load, obesity, genetics, nutrition, trauma and gender. In addition, it is not clear whether the heavy physical load associated with occupation is an important risk factor for IDD. Some studies have found that IDD is more common among athletes than the general population. Due to the complexity and multifactorial nature of IDD, its pathogenesis and risk factors are still unclear, which seriously hinders the rational stratification of LBP patients and limits the development of personalized treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date March 30, 2024
Est. primary completion date March 30, 2024
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - It meets the diagnostic criteria of lumbar disc degeneration; No previous history of spinal surgery; Good ability of independent behavior and cooperation in completing research; The patient is aware of this study and has signed the consent form. Exclusion Criteria: - Patients with spinal tumor, infection, tuberculosis and other diseases; Patients with claustrophobia; Parkinson's syndrome patients; Poor cooperation, Poor image quality; Patients with osteoporosis.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
CXCL2/CXCL8
Detecte CXCL2/8 content in nucleus pulposus and peripheral blood of patients in each group

Locations

Country Name City State
China Zhongda Hospital Nanjing Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Zhongda Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary CXCL2/8 content CXCL2/CXCL8 content of nucleus pulposus 1 month
See also
  Status Clinical Trial Phase
Completed NCT01496898 - Changes in Vaginal, Cervical and Uterine Microflora With Levonorgestrel Intrauterine Device Placement N/A
Recruiting NCT03825471 - Cranial Electrotherapy Stimulation on Anesthetics Consumption and Postoperative Pain N/A
Not yet recruiting NCT06199947 - Study of the Role of Oncostatin M in Head and Neck Squamous Cell Carcinoma N/A